Prof Andrea Necchi speaks to ecancer about the SunRISe-4, a randomised study on neoadjuvant gemcitabine intravesical system (TAR-200) plus cetrelimab or cetrelimab alone in patients with muscle-invasive bladder cancer (MIBC) who are ineligible for or refuse to receive a standard radical cystectomy.

Dr Necchi presented primary analysis and biomarker results, and reports that the combination improved the pathological complete response (pCR) compared to CET alone. He comments that it is a promising combination therapy to spare patients from toxicities of systemic therapies and that their findings have the potential to contribute to assessment of bladder saving approaches in the future.